



February 26, 2021

Canagliflozin (TA-7284) has been approved in Taiwan For Diabetic Nephropathy

Mitsubishi Tanabe Pharma Corporation (MTPC) (Head Office: Osaka; President & Representative Director, CEO: Hiroaki Ueno), announced today that Tai Tien Pharmaceuticals Co., Ltd. (Tai Tien) (Head Office: Taipei, Taiwan; General Manager Tony Chu), which is a consolidated subsidiary of MTPC obtained the regulatory approval of CANAGLU[®] (CANAGLU)(INN: canagliflozin; Japan names: CANAGLU[®] Tablets 100mg) for a treatment agent for diabetic nephropathy in Taiwan FDA on February 1, 2021.

Diabetic nephropathy, which is one of the three major complications of diabetes mellitus, is a disease that causes decreased renal function due to vascular disorder of the kidney and ultimately requires dialysis therapy. As the number of patients with diabetes increases, so does the number of patients with this disease, which is the biggest reason for introducing dialysis therapy. The development of therapies to improve this situation is an important issue not only from the viewpoint of patients' QOL but also from the viewpoint of health economics.

CANAGLU is a treatment agent for type 2 diabetes mellitus discovered by MTPC. CANAGLU was approved in March 2017 in Taiwan and has been marketed since March 2018.

For the indication of diabetic nephropathy, CANAGLU has already been approved in more than 49 countries worldwide by a licensee, Janssen Pharmaceuticals, Inc., and its affiliates, under the brand name INVOKANA.

In Japan, MTPC is currently conducting a phase 3 clinical study.

Tai Tien, which was established in 1987, has contributed to the treatment of patients with type 2 diabetes by supplying numerous products for lifestyle-related diseases. In Taiwan, the incidence and prevalence of ESRD are among the highest in the world*, and dialysis costs have a significant impact on healthcare finances. In addition, there are more than 2.2 million patients with diabetes mellitus, which has been increasing in recent years*, making diabetic nephropathy an issue that needs to be resolved as soon as possible.

By providing new options for the treatment of diabetes to a growing number of patients in the world, MTPC group show its continued resolve to improve their quality of life (QOL).

*2019 Taiwan Clinical Practice Guideline for Diabetic Kidney

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department

Media contacts: TEL:+81 6 6205 5119

<Reference>

■ **canagliflozin (Japan names: CANAGLU[®] Tablets 100mg)**

Canagliflozin (INN: canagliflozin; Japan names: CANAGLU[®] Tablets 100mg) is an SGLT2 inhibitor that originated in Japan. It is a treatment for type 2 diabetes mellitus which was discovered by Mitsubishi Tanabe Pharma and has its research roots in T-1095, the world's first orally bioavailable sodium glucose co-transporter inhibitor. CANAGLU[®] inhibits SGLT2, a transporter involved in the reabsorption of glucose in the renal tubules of the kidneys, suppresses the reabsorption of glucose, promotes the excretion of excessive glucose into the urine, and as a result, lowers the blood glucose level. Canagliflozin was approved in Japan, July 2014 followed by Taiwan in March 2017.

■ **Tai Tien Pharmaceuticals Co., Ltd (Tai Tien)**

Tai Tien Pharmaceuticals, which was established in Taipei in 1987, has marketed such products as HERBESSER[®], CONCOR[®] (Japan name: MAINTATE[®]), and LIVALO[®]. With the launch of CANAGLU[®], Tai Tien is contributing to the treatment of patients with type 2 diabetes in Taiwan by leveraging the foundation of its core therapeutic area for lifestyle-related diseases.